Key Highlights

• RYTELO net product Revenue reached $60.1 million in Q3 2026, up 5% from Q2 2026.

• The company reiterated full-year 2026 RYTELO revenue guidance at the mid-to-high end of $220–$240 million.

• Geron initiated a gated commercial launch in targeted European markets, with Germany availability expected by year-end.

• Cash, cash equivalents, restricted cash, and marketable securities stood at $339 million as of September 30, 2026.

Geron Corporation(NASDAQ:GERN), a commercial-stage biopharmaceutical company focused on hematology, delivered third-quarter 2026 results that reflected continued Demand growth for its lead product RYTELO (imetelstat) and marked the beginning of the company's international expansion.

RYTELO Revenue and Demand Trends

Net product revenue from RYTELO came in at $60.1 million for the three months ended September 30, 2026, representing a 5% increase compared to Q2 2026. Demand for the product grew by 10% quarter-over-quarter, with the estimated average number of patients on therapy rising by 400 to approximately 9,350. Ordering accounts increased by roughly 8% during the quarter, reaching approximately 1,700. Community practices were cited as the primary driver of demand growth, which management views as an indicator of a potentially extended growth trajectory in the United States.

Geron reiterated its full-year RYTELO net product revenue guidance at the mid-to-high end of the $220 million to $240 million range and lowered its total operating expenses forecast to $220–$230 million.

European Expansion Underway

A notable development in the quarter was Geron's initiation of a gated commercial launch to bring RYTELO to eligible patients with lower-risk myelodysplastic syndromes in targeted European markets. The company expects RYTELO to be available in Germany by the end of 2026, with France availability anticipated in 2027. This expansion marks a meaningful step in broadening the geographic footprint of the therapy beyond the United States.

Financial Overview

Total revenues for Q3 2026 were $60.4 million, compared to $44.1 million in the same quarter last year. GAAP Cost of Goods Sold was $7.2 million, while selling, general, and administrative expenses were $44.2 million. Research and Development expenses totalled $12.2 million. Geron reported a net loss of $5.6 million, or $0.01 per diluted share, for the quarter, compared to a net loss of $37.3 million, or $0.06 per diluted share, in Q3 2025. The narrowing of the net loss reflects RYTELO's growing revenue contribution.

Cash, cash equivalents, restricted cash, and marketable securities totalled $339 million as of September 30, 2026.

Pipeline and Clinical Activity

On the clinical front, Geron presented data at several medical conferences during and after the quarter. At the Society of Hematologic Oncology annual meeting, the company exhibited three posters, including real-world evidence of imetelstat treatment in lower-risk MDS that was described as generally consistent with findings from the Phase 3 IMerge trial. The company also delivered presentations at the annual meetings of the Japanese Society of Hematology and the German, Austrian, and Swiss Societies for Hematology.

RYTELO was nominated for the 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases, a recognition of its therapeutic contribution in lower-risk MDS.

What Comes Next

Geron's Q3 results underscore a company in transition from early commercial ramp to sustained revenue generation, with the European launch opening a new chapter. Continued demand growth in the US, combined with narrowing losses, points to a trajectory of increasing financial self-sufficiency.